Heron Therapeutics (HRTX) Misses Q1 EPS by 15c

Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.63), $0.15 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $22.4 million versus the consensus estimate of $22.61 million.

GUIDANCE:

Heron Therapeutics sees FY2022 revenue of $89-93 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
• Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance